ClinicalTrials.gg
RecruitingNCT07569042Updated May 6, 2026

A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma

A Phase 1/2 interventional study of NBM-BMX Capsule and Temozolomide in Malignant Neoplasm of Brain, sponsored by Novelwise Pharmaceutical Corporation. Recruiting at 3 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Novelwise Pharmaceutical Corporation · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Brain Neoplasms with a site in Taiwan — 19 open to participants now, 20 under way, 2 of them phase 3. Brain Neoplasms · Taiwan.

Planned enrollment
35th of 41
15 · median 100
Started
2026
the only one that year
Phase 1/2
4 of 53
3 open now
Primary completion
2029-09
later than 18 of 19 live
Registered
51st of 53
by date
Lead sponsor
2 of 53
Novelwise Pharmaceutical Corporation

Among the 53 studies in Brain Neoplasms with a site in Taiwan, this one is the 35th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1/2, reaches primary completion later than 18 of the 19 other live ones, and was the 51st registered.

Brain Neoplasms

2,442 studies on the registry are indexed under Brain Neoplasms; 543 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

19 of the 53 studies in Brain Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 427 Brain Neoplasms studies recruiting now, 287 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Brain Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

This clinical trial is a rollover study designed to provide continued access to NBM-BMX and temozolomide (TMZ) for eligible participants with newly diagnosed glioblastoma who have completed the designated treatment in Study NBM-BMX-003 (the parent study), and to evaluate the long-term safety and efficacy of NBM-BMX administered in combination with TMZ.

Read the detailed description

This is a multi-center, open-label, single-arm, rollover study designed to provide participants with newly diagnosed glioblastoma who have completed Study NBM-BMX-003 (the parent study) with continued access to study treatment. Eligible participants will transition into this study to continue receiving study drugs (NBM-BMX and temozolomide) at the same doses and schedules as in the parent study.

For participants enrolled in the dose-escalation cohorts of the parent study who received lower doses of NBM-BMX, escalation to a higher dose demonstrated to be safe in the parent study may be permitted with Sponsor approval.

Participants may continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or up to 12 cycles of treatment, whichever occurs first.

03

Conditions studied

  • Malignant Neoplasm of Brain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for the study:

  1. Have completed or currently enrolled in Arm B of Study NBM-BMX-003 (the parent study), and in the opinion of the Investigator, may derive clinical benefit from continued treatment with study drugs.
  2. confirmed glioblastoma.
  3. Can enroll into this rollover study within 35 days after completing the last dose of NBM-BMX in the parent study.
  4. Have signed and dated the form.
  5. performance status (KPS) ≥ 60 at enrollment in this study.
  6. Adequate organ functions as defined by the following criteria:

    1. Serum (AST) and serum alanine transaminase (ALT) ≤ 3 × (ULN)
    2. Total serum ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN
    3. (ANC) ≥ 1,000/µL
    4. ≥ 75,000/µL
    5. ≥ 8.0 g/dL
    6. Non-indexed estimated (eGFR) ≥ 50 mL/min
  7. Women of must have a negative pregnancy test performed within 14 days before the first dose of this study.
  8. Men and women of childbearing potential must agree to use acceptable methods throughout the study period and for at least 6 months after the final dose of temozolomide.

    Acceptable contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.

  9. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

Exclusion criteria

Exclusion Criteria:

Participants with any of the following will be excluded from the study:

  1. Currently receive or plan to receive anti-cancer treatments other than the study drugs including Gliadel wafer implant or tumor treating fields (TTFields).
  2. Permanently discontinued from the parent study due to unacceptable toxicity, non-compliance with study procedures, withdrawal of consent, or any other reason.
  3. A positive test for (HBsAg) and/or (anti-HCV antibody), unless the HBV DNA level and/or HCV RNA level is below the limit of detection.
  4. > 480 msec
  5. Currently taking strong inhibitors (e.g., gemfibrozil) or inducers of CYP2C8.
  6. Have known reaction to temozolomide, dacarbazine or NBM-BMX.
  7. Have difficulty swallowing (including those require nasogastric tube) or with impaired absorption of oral medications.
  8. Female who are pregnant or breastfeeding.
  9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgement of the Investigator and/or sponsor, excess risks associated with study participation or study drug administration.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Combination therapy in glioblastoma

    Subjects with newly diagnosed glioblastoma who have completed Study NBM-BMX-003 will transition into this study to continue receiving study drugs (NBM-BMX and temozolomide) at the same doses and schedules as in the parent study.

    Drug: NBM-BMX Capsule · Drug: Temozolomide

Interventions

  • DrugNBM-BMX Capsule

    Each capsule contains 100 mg of the active ingredient.

  • Temodal will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.

    Also known as: TMZ

06

What researchers measure

Primary outcomes

  1. Frequency, types, severity, and relationship to NBM-BMX of adverse events (AEs)

    To evaluate the long-term safety and tolerability of NBM-BMX in combination with temozolomide.

    Time frame: Through study completion, an average of 1 year.

  2. Progression-free survival (PFS) and overall survival (OS)

    To assess the preliminary long-term efficacy of the combination therapy.

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 of 3 sites recruiting
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
    Not yet recruiting
    • Ann-Shung Lieu, M.D. · Contact+886 7 3121101
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
    Not yet recruiting
    • Wen-Yu Cheng, M.D. · Contact+886 4 23592525
  • Linkou Chang-Gung Memorial Hospital
    Taoyuan City, 333, Taiwan
    Recruiting
    • Kuo-Chen Wei, M.D. · Contact+886 3 3281200
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2029, 41 months after the start.

Of 73 phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 105. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 6, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Dec 31, 2030
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07569042
Lead sponsor
Novelwise Pharmaceutical Corporation
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Apr 20, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
May 6, 2026

Study contacts

Chia-Chung Hou, Ph.D.
Contact
alison.hou@novelwisepharma.com
886 2 26559109 ext. 101
Cherry Hsu
Contact
cherry.hsu@effpha.com
886 2 27891060 ext. 509

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion